Epoch Investment Partners Inc. Invests $26.49 Million in MAXIMUS, Inc. (MMS) Stock

Epoch Investment Partners Inc. purchased a new position in MAXIMUS, Inc. (NYSE:MMS) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 407,204 shares of the health services provider’s stock, valued at approximately $26,493,000. Epoch Investment Partners Inc. owned 0.63% of MAXIMUS as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. increased its position in MAXIMUS by 6.5% in the 2nd quarter. BlackRock Inc. now owns 7,298,102 shares of the health services provider’s stock worth $453,284,000 after buying an additional 445,353 shares during the period. Victory Capital Management Inc. increased its position in shares of MAXIMUS by 7.8% during the third quarter. Victory Capital Management Inc. now owns 3,960,599 shares of the health services provider’s stock valued at $257,677,000 after purchasing an additional 286,792 shares during the period. Van Berkom & Associates Inc. increased its position in shares of MAXIMUS by 2.3% during the third quarter. Van Berkom & Associates Inc. now owns 1,406,804 shares of the health services provider’s stock valued at $91,527,000 after purchasing an additional 31,403 shares during the period. Northern Trust Corp increased its position in shares of MAXIMUS by 1.8% during the second quarter. Northern Trust Corp now owns 1,123,555 shares of the health services provider’s stock valued at $69,785,000 after purchasing an additional 20,408 shares during the period. Finally, Thompson Siegel & Walmsley LLC increased its position in shares of MAXIMUS by 8.2% during the third quarter. Thompson Siegel & Walmsley LLC now owns 1,059,800 shares of the health services provider’s stock valued at $68,951,000 after purchasing an additional 80,099 shares during the period. 93.29% of the stock is currently owned by institutional investors.

MMS opened at $69.86 on Friday. The company has a market cap of $4.54 billion, a PE ratio of 20.55, a PEG ratio of 1.93 and a beta of 1.03. MAXIMUS, Inc. has a 1 year low of $60.00 and a 1 year high of $72.71.

MAXIMUS (NYSE:MMS) last released its quarterly earnings data on Tuesday, November 20th. The health services provider reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.72 by ($0.01). The firm had revenue of $558.50 million for the quarter, compared to the consensus estimate of $587.58 million. MAXIMUS had a net margin of 9.23% and a return on equity of 20.23%. The business’s revenue for the quarter was down 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.81 earnings per share. On average, analysts predict that MAXIMUS, Inc. will post 3.66 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 30th. Stockholders of record on Thursday, November 15th were given a dividend of $0.25 per share. The ex-dividend date was Wednesday, November 14th. This is a boost from MAXIMUS’s previous quarterly dividend of $0.05. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.43%. MAXIMUS’s payout ratio is currently 29.41%.

A number of research firms have recently issued reports on MMS. Canaccord Genuity boosted their price objective on MAXIMUS from $64.00 to $67.00 and gave the company a “hold” rating in a research report on Wednesday, October 10th. ValuEngine upgraded MAXIMUS from a “hold” rating to a “buy” rating in a research report on Friday, November 30th. Finally, Zacks Investment Research upgraded MAXIMUS from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $72.00.

In related news, General Counsel David Francis sold 6,220 shares of the business’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $63.86, for a total value of $397,209.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Russell A. Beliveau sold 1,000 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $63.86, for a total value of $63,860.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 133,124 shares of company stock worth $9,005,450. 3.10% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/epoch-investment-partners-inc-invests-26-49-million-in-maximus-inc-mms-stock.html.

About MAXIMUS

MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.

See Also: What is a Swap?

Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MAXIMUS, Inc. (NYSE:MMS).

Institutional Ownership by Quarter for MAXIMUS (NYSE:MMS)

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply